Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275
Authors:
Adam C Palmer
Benjamin Izar
Haeun Hwangbo
Peter K Sorger
Affiliated Authors:
Benjamin Izar
Columbia Affiliation:
Subjects:
Cancer Immunotherapy (OpenAlex Topic)
Genomic Landscape of Cancer and Mutational Signatures (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Immune Checkpoint Inhibitors (MeSH)
Melanoma (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1158/1078-0432.ccr-21-2275
PMID:
35045958
DOI:
10.1158/1078-0432.ccr-21-2275
Journal:
Clinical Cancer Research
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View OpenAlex Record
View Scopus Record
View Web of Science Record

Record Created: